Uveitis - Pipeline Review, H2 2020

September 2020 | 266 pages | ID: U441FED1C48EN
Global Markets Direct

Abstracts

Uveitis - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uveitis - Pipeline Review, H2 2020, provides an overview of the Uveitis (Ophthalmology) pipeline landscape.
Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uveitis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 9, 6, 1, 1, 43 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Uveitis (Ophthalmology).
• The pipeline guide reviews pipeline therapeutics for Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Uveitis (Ophthalmology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Uveitis (Ophthalmology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Uveitis - Overview
Uveitis - Therapeutics Development
Uveitis - Therapeutics Assessment
Uveitis - Companies Involved in Therapeutics Development
Uveitis - Drug Profiles
Uveitis - Dormant Projects
Uveitis - Discontinued Products
Uveitis - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Uveitis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Uveitis - Pipeline by Aciont Inc, H2 2020
Uveitis - Pipeline by Active Biotech AB, H2 2020
Uveitis - Pipeline by Afecta Pharmaceuticals Inc, H2 2020
Uveitis - Pipeline by Akari Therapeutics Plc, H2 2020
Uveitis - Pipeline by Aldeyra Therapeutics Inc, H2 2020
Uveitis - Pipeline by Alpine Immune Sciences Inc, H2 2020
Uveitis - Pipeline by Alvotech ehf, H2 2020
Uveitis - Pipeline by Apidel SA, H2 2020
Uveitis - Pipeline by Apitope International NV, H2 2020
Uveitis - Pipeline by Bonac Corp, H2 2020
Uveitis - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2020
Uveitis - Pipeline by Dobecure SL, H2 2020
Uveitis - Pipeline by E&B Technologies LLC, H2 2020
Uveitis - Pipeline by Elasmogen Ltd, H2 2020
Uveitis - Pipeline by Eleusis Ltd, H2 2020
Uveitis - Dormant Projects, H2 2020
Uveitis - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Uveitis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020

COMPANIES MENTIONED

Aciont Inc
Active Biotech AB
Afecta Pharmaceuticals Inc
Akari Therapeutics Plc
Aldeyra Therapeutics Inc
Alpine Immune Sciences Inc
Alvotech ehf
Apidel SA
Apitope International NV
Bonac Corp
Chugai Pharmaceutical Co Ltd
Dobecure SL
E&B Technologies LLC
Elasmogen Ltd
Eleusis Ltd
Emerald Bioscience Inc
Enzo Biochem Inc
EyePoint Pharmaceuticals Inc
Eyevensys SAS
EyGen Ltd
F. Hoffmann-La Roche Ltd
Galapagos NV
HanAll Biopharma Co Ltd
HanAll Biopharma Co Ltd
Idogen AB
InSight Biopharmaceuticals Ltd
Kodiak Sciences Inc
Kubota Vision Inc
Kv1.3 Therapeutics
MetrioPharm AG
Mitotech SA
Naegis Pharmaceuticals Inc
NeuClone Pty Ltd
Novaliq GmbH
Novartis AG
Oculis SA
OKYO Pharma Ltd
OncoNOx ApS
ONL Therapeutics Inc
Orchid Pharma Ltd
OSE Immunotherapeutics
Palatin Technologies Inc
Panag Pharma Inc
Panoptes Pharma GesmbH
Pharmapraxis
Re-Pharm Ltd
Reven Pharmaceuticals Inc
RiniSight Inc
Ripple therapeutics Corp
Santen Pharmaceutical Co Ltd
SFA Therapeutics LLC
Sol-Gel Technologies Ltd
Sparrow Pharmaceuticals Inc
Tarsius Pharma Ltd
Tianjin Pharmaceuticals Group Co Ltd
Vyome Therapeutics Inc